<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866034</url>
  </required_header>
  <id_info>
    <org_study_id>CETRO Trial</org_study_id>
    <secondary_id>CCMO: NL23973.041.08</secondary_id>
    <secondary_id>METC: 08-262/G-K</secondary_id>
    <nct_id>NCT00866034</nct_id>
  </id_info>
  <brief_title>Cetrotide Treatment Optimization</brief_title>
  <official_title>Prospective, Multicenter,Randomized Controlled Trial Towards Identifying the Optimal GnRH Antagonist Treatment Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bart CJM Fauser</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      In daily practice fertility treatment is increasingly patient focused and innovative
      medication and standardized treatment guidelines are being developed to improve patient
      convenience.

      GnRH antagonist cotreatment to prevent premature luteinization during ovarian stimulation for
      IVF and ICSI greatly reduces the burden of treatment, partly by reducing the number of
      injections by around 21 compared with the optimal GnRH agonist 'long' protocol. However, the
      optimal GnRH antagonist protocol is still not known. There are a number of reasons to suggest
      that both the simplicity of treatment and clinical outcomes could be further improved by
      commencing GnRH antagonist treatment on the same day on which ovarian stimulation is started.
      These include more synchronized follicle development and reduced rates of premature
      luteinization. This study will investigate whether a novel early fixed start protocol
      improves outcomes in comparison to the widely employed late fixed start protocol.

      Objective:

      To demonstrate whether an early fixed start antagonist protocol improves the live birth rate
      compared with a late fixed start antagonist protocol by 5%.

      Study design:

      Prospective, multicenter, investigator sponsored, randomized controlled trial

      Study population:

        -  Normo-ovulatory women &lt; 39 years with an indication for IVF or ICSI

        -  No more than 2 previous unsuccessful IVF/ICSI cycles

        -  BMI â‰¤ 32 kg/m2

      Intervention:

      Two different GnRH antagonist treatment protocols used in daily practice will be compared.
      Patients will be randomized to receive one of the following two treatments:

        -  Early fixed start: start GnRH antagonist treatment with Cetrotide 0.25 mg on the same
           day as FSH, cycle day 2.

        -  Late fixed start: FSH will be administered from cycle day 2. GnRH antagonist treatment
           with Cetrotide 0.25 mg will commence on cycle day 6.

      Main study parameters/endpoints:

      The primary endpoint is the live birth rate per started cycle. A secondary endpoint is the
      number of embryos available for transfer.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness:

      In addition to recording clinical outcomes, endocrine studies will be carried out at the UMC
      Utrecht in a sample of 200 participants who will be subjected to blood sampling at three
      points during the treatment cycle: prior to commencing treatment on cycle day 2, cycle day 6
      and the day of hCG administration.The aim of this substudy was therefore to prospectively
      compare the effect of a cycle day 2 versus cycle day 6 fixed start GnRH antagonist protocol
      on LH, estradiol and progesterone levels in the mid and late follicular phase. In order to
      investigate whether the early fixed protocol exerts a significant extra burden on patients
      compared to the late start protocol, another group of 200 participants at the UMCU will be
      requested to complete the HADS questionnaire (Hospital Anxiety and Depression Scale).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to limited rate of patient inclusion
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live Birth Rate Per Started Cycle and Live Birth From Cryopreserved Embryos Originating From, and Occurring Within 6 Months of the Initial Treatment Cycle Will be Included in the Total Live Birth Rate Per Started Cycle.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Ongoing Pregnancy Rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Endocrine Profile in the Early, Mid and Late Follicular Phase.</measure>
    <time_frame>2 years</time_frame>
    <description>difference in endocrine profile between the 2 arms during the mid and late follicular phase
influence of early elevated follicular phase progesterone levels on clinical outcome</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">617</enrollment>
  <condition>In Vitro Fertilization</condition>
  <condition>Intracytoplasmic Sperm Injection</condition>
  <arm_group>
    <arm_group_label>CD2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrotide (Ovarian stimulation)</intervention_name>
    <description>Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2</description>
    <arm_group_label>CD2</arm_group_label>
    <other_name>Gonal-F</other_name>
    <other_name>Cetrorelix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetrotide (Ovarian stimulation)</intervention_name>
    <description>Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.</description>
    <arm_group_label>CD6</arm_group_label>
    <other_name>Gonal-F</other_name>
    <other_name>Cetrorelix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normo-ovulatory women &lt; 39 years with an indication for IVF or ICSI

        Exclusion Criteria:

          -  More than 2 previous unsuccessful IVF/ICSI cycles

          -  BMI &gt; 32 kg/m2
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick S Macklon, Prof, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <results_first_submitted>October 17, 2013</results_first_submitted>
  <results_first_submitted_qc>October 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2013</results_first_posted>
  <last_update_submitted>February 4, 2014</last_update_submitted>
  <last_update_submitted_qc>February 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Bart CJM Fauser</investigator_full_name>
    <investigator_title>Professor of Reproductive Medicine and Gynecology</investigator_title>
  </responsible_party>
  <keyword>Cetrotide</keyword>
  <keyword>IVF</keyword>
  <keyword>ICSI</keyword>
  <keyword>Treatment protocol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetrorelix</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: September 2009 - July 2011 Six hundred and seventeen women undergoing IVF or ICSI were recruited from the IVF outpatient clinics of 13 fertility centres.</recruitment_details>
      <pre_assignment_details>None were excluded before assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Early Start CD2</title>
          <description>Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.</description>
        </group>
        <group group_id="P2">
          <title>Late Start CD6</title>
          <description>Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="308"/>
                <participants group_id="P2" count="309"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="292"/>
                <participants group_id="P2" count="301"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Early Start CD2</title>
          <description>Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.</description>
        </group>
        <group group_id="B2">
          <title>Late Start CD6</title>
          <description>Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="308"/>
            <count group_id="B2" value="309"/>
            <count group_id="B3" value="617"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="3.9"/>
                    <measurement group_id="B2" value="32.2" spread="4.2"/>
                    <measurement group_id="B3" value="32.2" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="308"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Live Birth Rate Per Started Cycle and Live Birth From Cryopreserved Embryos Originating From, and Occurring Within 6 Months of the Initial Treatment Cycle Will be Included in the Total Live Birth Rate Per Started Cycle.</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Start CD2</title>
            <description>Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.</description>
          </group>
          <group group_id="O2">
            <title>Late Start CD6</title>
            <description>Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth Rate Per Started Cycle and Live Birth From Cryopreserved Embryos Originating From, and Occurring Within 6 Months of the Initial Treatment Cycle Will be Included in the Total Live Birth Rate Per Started Cycle.</title>
          <units>Cumulative live birth rate (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Ongoing Pregnancy Rate</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Early Start CD2</title>
            <description>Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.</description>
          </group>
          <group group_id="O2">
            <title>Late Start CD6</title>
            <description>Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Ongoing Pregnancy Rate</title>
          <units>cumulative ongoing pregnancy rate (%)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="308"/>
                <count group_id="O2" value="309"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6"/>
                    <measurement group_id="O2" value="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Endocrine Profile in the Early, Mid and Late Follicular Phase.</title>
        <description>difference in endocrine profile between the 2 arms during the mid and late follicular phase
influence of early elevated follicular phase progesterone levels on clinical outcome</description>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Early Start CD2</title>
          <description>Early fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2, together with the initiation of daily treatment with exogenous gonadotropins.</description>
        </group>
        <group group_id="E2">
          <title>Late Start CD6</title>
          <description>Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6. As in the other arm of the study, exogenous gonadotropins will commence on cycle day 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="308"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>OHSS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="308"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.6</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="308"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>cancellation due to hyperresponse</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="308"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="309"/>
              </event>
              <event>
                <sub_title>cancellation due to hyporesponse</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="308"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="309"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated prematurely because no significant difference was observed in clinical outcome after 617 inclusions. A much larger population would be needed to detect a small significant difference in favour of either study arm.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Ouijdane Hamdine, MD</name_or_title>
      <organization>UMC Utrecht</organization>
      <phone>+31-88-7557524</phone>
      <email>O.Hamdine@umcutrecht.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

